MethylGene news from FierceBiotech
NewsFDA puts partial clinical hold on MethylGene program
Canada's MethylGene says that as a result of its voluntary decision to halt enrollment in a new drug study, the FDA has put a partial clinical hold on its lead development program in cancer. The Read more...
ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc
> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88. Read more...
ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...
> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a Read more...
ALSO NOTED: GSK cuts 5,000 jobs; Codexis opens Singapore lab; Reliant sets IPO terms;and much more...
> The closure of a GlaxoSmithKline's Puerto Rican plant has kicked off the plan to cut 5,000 jobs. Read more...
| Press ReleasesPRESS RELEASE: Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference - Safety and response data from Phase I/II MGCD0103 combination trial with Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets